Baxiva’s platform enables the rapid development of vaccines targeting the serotype-specific polysaccharides of Gram-negative bacteria. Our proprietary chemical conjugation strategy links the bacterial polysaccharides to virus-like particles (VLPs), producing highly immunogenic glycoconjugates. This approach streamlines the development of highly multivalent vaccines targeting both known and emerging bacterial pathogens—offering a powerful tool in the fight against drug-resistant infections.